NVO
NOVO NORDISK Semaglutide Trial in Children Aged 6 to 11 Hits Endpoint
In the STEP Young phase 3 trial, 40.4% of children treated with semaglutide were no longer classified as having obesity after 68 weeks, versus none on placebo.
NVO
In the STEP Young phase 3 trial, 40.4% of children treated with semaglutide were no longer classified as having obesity after 68 weeks, versus none on placebo.
NVO
The Danish drugmaker's head-to-head Phase 3 study of CagriSema versus Eli Lilly's tirzepatide in type 2 diabetes is now listed as completed.